FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785100978> ?p ?o ?g. }

• W2785100978 endingPage "e438" @default.
• W2785100978 startingPage "e438" @default.
• W2785100978 abstract "Background Glycine receptor alpha-1 subunit (GlyRα1)-immunoglobulin G (IgG) is diagnostic of stiff-person syndrome (SPS) spectrum but has been reported detectable in other neurologic diseases for which significance is less certain. Methods To assess GlyRα1-IgGs as biomarkers of SPS spectrum among patients and controls, specimens were tested using cell-based assays (binding [4°C] and modulating [antigen endocytosing, 37°C]). Medical records of seropositive patients were reviewed. Results GlyRα1-IgG (binding antibody) was detected in 21 of 247 patients with suspected SPS spectrum (8.5%) and in 8 of 190 healthy subject sera (4%) but not CSF. Among 21 seropositive patients, 20 had confirmed SPS spectrum clinically, but 1 was later determined to have a functional neurologic disorder. Sera from 9 patients with SPS spectrum , but not 7 controls, nor the functional patient, caused GlyRα1 modulation (100% specificity). SPS spectrum phenotypes included progressive encephalomyelitis with rigidity and myoclonus (PERM) (8), classic SPS (5), stiff limb (5), stiff trunk (1), and isolated exaggerated startle (hyperekplexia, 1). Neuropsychiatric symptoms present in 12 patients (60%) were anxiety (11), depression (6), and delirium (3). Anxiety was particularly severe in 3 patients with PERM. Objective improvements in SPS neurologic symptoms were recorded in 16 of 18 patients who received first-line immunotherapy (89%, 9/10 treated with corticosteroids, 8/10 treated with IVIg, 3/4 treated with plasma exchange, and 1 treated with rituximab). Treatment-sparing maintenance strategies were successful in 4 of 7 patients (rituximab [2/3], azathioprine [1/1], and mycophenolate [1/3]). Conclusions GlyRα1-modulating antibody improves diagnostic specificity for immunologically treatable SPS spectrum disorders. Classification of evidence This study provides Class IV evidence that GlyRα1-modulating antibody accurately identifies patients with treatable SPS spectrum disorders." @default.
• W2785100978 created "2018-02-02" @default.
• W2785100978 creator A5001020438 @default.
• W2785100978 creator A5010482465 @default.
• W2785100978 creator A5013618501 @default.
• W2785100978 creator A5026428280 @default.
• W2785100978 creator A5032795537 @default.
• W2785100978 creator A5053780989 @default.
• W2785100978 creator A5055122406 @default.
• W2785100978 creator A5080625507 @default.
• W2785100978 creator A5088136783 @default.
• W2785100978 date "2018-01-24" @default.
• W2785100978 modified "2023-09-30" @default.
• W2785100978 title "Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders" @default.
• W2785100978 cites W1966578260 @default.
• W2785100978 cites W1970410994 @default.
• W2785100978 cites W1971610936 @default.
• W2785100978 cites W1982151760 @default.
• W2785100978 cites W2006971985 @default.
• W2785100978 cites W2024217354 @default.
• W2785100978 cites W2042810700 @default.
• W2785100978 cites W2061056490 @default.
• W2785100978 cites W2065371727 @default.
• W2785100978 cites W2067927161 @default.
• W2785100978 cites W2075528611 @default.
• W2785100978 cites W2103644035 @default.
• W2785100978 cites W2155721592 @default.
• W2785100978 cites W2162512104 @default.
• W2785100978 cites W2325022026 @default.
• W2785100978 cites W2333301957 @default.
• W2785100978 cites W2345647060 @default.
• W2785100978 doi "https://doi.org/10.1212/nxi.0000000000000438" @default.
• W2785100978 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5813079" @default.
• W2785100978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29464188" @default.
• W2785100978 hasPublicationYear "2018" @default.
• W2785100978 type Work @default.
• W2785100978 sameAs 2785100978 @default.
• W2785100978 citedByCount "48" @default.
• W2785100978 countsByYear W27851009782018 @default.
• W2785100978 countsByYear W27851009782019 @default.
• W2785100978 countsByYear W27851009782020 @default.
• W2785100978 countsByYear W27851009782021 @default.
• W2785100978 countsByYear W27851009782022 @default.
• W2785100978 countsByYear W27851009782023 @default.
• W2785100978 crossrefType "journal-article" @default.
• W2785100978 hasAuthorship W2785100978A5001020438 @default.
• W2785100978 hasAuthorship W2785100978A5010482465 @default.
• W2785100978 hasAuthorship W2785100978A5013618501 @default.
• W2785100978 hasAuthorship W2785100978A5026428280 @default.
• W2785100978 hasAuthorship W2785100978A5032795537 @default.
• W2785100978 hasAuthorship W2785100978A5053780989 @default.
• W2785100978 hasAuthorship W2785100978A5055122406 @default.
• W2785100978 hasAuthorship W2785100978A5080625507 @default.
• W2785100978 hasAuthorship W2785100978A5088136783 @default.
• W2785100978 hasBestOaLocation W27851009781 @default.
• W2785100978 hasConcept C118552586 @default.
• W2785100978 hasConcept C126322002 @default.
• W2785100978 hasConcept C159654299 @default.
• W2785100978 hasConcept C181199279 @default.
• W2785100978 hasConcept C185592680 @default.
• W2785100978 hasConcept C203014093 @default.
• W2785100978 hasConcept C2776443654 @default.
• W2785100978 hasConcept C2777154362 @default.
• W2785100978 hasConcept C2777756961 @default.
• W2785100978 hasConcept C2780653079 @default.
• W2785100978 hasConcept C35599011 @default.
• W2785100978 hasConcept C515207424 @default.
• W2785100978 hasConcept C55493867 @default.
• W2785100978 hasConcept C558461103 @default.
• W2785100978 hasConcept C71924100 @default.
• W2785100978 hasConcept C90924648 @default.
• W2785100978 hasConcept C9497952 @default.
• W2785100978 hasConceptScore W2785100978C118552586 @default.
• W2785100978 hasConceptScore W2785100978C126322002 @default.
• W2785100978 hasConceptScore W2785100978C159654299 @default.
• W2785100978 hasConceptScore W2785100978C181199279 @default.
• W2785100978 hasConceptScore W2785100978C185592680 @default.
• W2785100978 hasConceptScore W2785100978C203014093 @default.
• W2785100978 hasConceptScore W2785100978C2776443654 @default.
• W2785100978 hasConceptScore W2785100978C2777154362 @default.
• W2785100978 hasConceptScore W2785100978C2777756961 @default.
• W2785100978 hasConceptScore W2785100978C2780653079 @default.
• W2785100978 hasConceptScore W2785100978C35599011 @default.
• W2785100978 hasConceptScore W2785100978C515207424 @default.
• W2785100978 hasConceptScore W2785100978C55493867 @default.
• W2785100978 hasConceptScore W2785100978C558461103 @default.
• W2785100978 hasConceptScore W2785100978C71924100 @default.
• W2785100978 hasConceptScore W2785100978C90924648 @default.
• W2785100978 hasConceptScore W2785100978C9497952 @default.
• W2785100978 hasIssue "2" @default.
• W2785100978 hasLocation W27851009781 @default.
• W2785100978 hasLocation W27851009782 @default.
• W2785100978 hasLocation W27851009783 @default.
• W2785100978 hasLocation W27851009784 @default.
• W2785100978 hasOpenAccess W2785100978 @default.
• W2785100978 hasPrimaryLocation W27851009781 @default.
• W2785100978 hasRelatedWork W1969095581 @default.
• W2785100978 hasRelatedWork W2019506747 @default.

• next